We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/1/2021 14:22 | Am looking for £2 next stop before Covid trial comes out. | deanmatlazin | |
13/1/2021 14:19 | Reb your one of a kind, US disregards at its own peril. Regeneron has the Cash to buy this for many billions, mark my words. Oh Regeneron is American is it not! | impala391 | |
13/1/2021 14:16 | You emphasise my point Tom, I say again the US only take what they want seriously... | rebelwithacause1 | |
13/1/2021 14:13 | Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it has hired an industry veteran with experience of successfully developing blockbuster monoclonal antibody products as its chief medical officer. At Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Dr Neil Graham was “instrumental& During his tenure, he also led the product development for Kevzara, an IL-6R antibody for rheumatoid arthritis, which is now also being used to fight coronavirus (COVID-19) symptoms. Graham’s experience will be crucial during the clinical evolution of Tiziana candidates Foralumab, a monoclonal antibody (mAB) treatment for autoimmune and inflammatory diseases, Milciclib, for cancer, and TZLS-501, its anti-IL-6 drug. He hailed as a potential “game-changer& In a statement, Tiziana chairman and founder, Gabriele Cerrone, said of Graham: “His knowledge and experience at Regeneron in developing blockbuster monoclonal antibody drugs such as Dupixent will be invaluable in developing Foralumab and our anti-IL-6 drug, TZLS-501.” As well as a 10-year stint at Regeneron, Graham has held roles with drug developers Vertex, Trimeris and Glaxo Welcome and he was also an associate professor at John Hopkins University in the US. | yidarmytom | |
13/1/2021 13:57 | Or the other way Puff, wide disparity between the two listings...Imp the US only take what they want seriously! | rebelwithacause1 | |
13/1/2021 13:48 | Looks like the USA will be playing catch up with the UK today looking at pre market. | jpuff | |
13/1/2021 13:11 | glad you are posting andy - you are such a Green Flag bud | yidarmytom | |
13/1/2021 13:00 | NastyDump isInthe making UrsTruly allBuTT o | andymunchkin | |
13/1/2021 12:01 | My cartalk is only to wind up the shorters :) | aberloon2 | |
13/1/2021 11:51 | Nasdaq will have to take this seriously now!! aye Reb. | impala391 | |
13/1/2021 11:16 | Market obviously likes the new man on the team | ayl30 | |
13/1/2021 10:38 | Soon be £2+ and £5 target for reason.Way under value.Brazil update imminent and we also going main market on 21st. | 36jay | |
13/1/2021 10:24 | but it's a red flag when bulletin board posts talk of new cars | yidarmytom | |
13/1/2021 10:21 | I have pre-ordered a Lordstown Motors Endurance because I wanted a Truck not a sedan - I spend half my time in the U.S. so didn't want a Tesla - they are everywhere! Regeneron grew from $3bn to $50bn in short order on the back of a few antibodies. | yidarmytom | |
13/1/2021 10:13 | Yes Tesla great choice fellow genuine investor. | mark0419 | |
13/1/2021 10:11 | Relentless buying now..... WowHope small crow is going to be OK with mouldy bread this winter.hehe | mark0419 | |
13/1/2021 10:09 | Looking at my TESLA catalogue now. | aberloon2 | |
13/1/2021 10:09 | Dr. Graham stated: "I am excited to join Tiziana to help develop its unique monoclonal antibody platform for autoimmune diseases. Tiziana's ability to deliver antibody immunotherapeutics via oral and nasal routes is a potential game-changer for patients and physicians alike".If he can see the potential working for a billion dollar company like Regeneron then that's good enough for me.The credentials are insane.GOOD LUCK TO ALL GENUINE INVESTORS | mark0419 | |
13/1/2021 09:38 | Lets see DM... | rebelwithacause1 | |
13/1/2021 09:35 | Wonder what boiler room some are associated with and how much do they receive for each negative comment written. So sad. Currently flicking through my BMW new car catalogue. Wonder which one to choose. This has been a dream investment for me. Cheers. | mark0419 | |
13/1/2021 09:32 | I am sure Dr Graham can grow this company from a quarter of billion £ to few billions...at least :) | deanmatlazin | |
13/1/2021 09:27 | Lets not get ahead ourselves just yet...the surge was expected in the run-up to main market listing (as my comments stated last Dec) but it won't last! | rebelwithacause1 | |
13/1/2021 09:26 | This is looking amazing how did they pull that off...... Like signing Lionel Messi. | mark0419 | |
13/1/2021 09:21 | Employing Dr Graham with extensive experience together with Tiziana’s world class drug awaiting to go few trials....sky is the limit where there share price should go up to :) | deanmatlazin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions